Dr Nicolas Schauer is a health care professional brings over 16+ years of experience.

Dr Nicolas brings a distinct perspective to the health and preventive area. His experience in management and track record of driving growth, together with his expertise in strategic planning and execution, have helped numerous firms grow and develop successfully.

He started working with De Ruiter Seeds in the Netherlands as a Metabolomic Specialist after finishing a post-doctoral research scholarship as a Research Scientist in Metabolomics at the Max-Planck Institute of Molecular Plant Physiology, Potsdam Area, Germany.

Currently, Dr. Nicolas is heading as the Chief Executive Officer (CEO) of Aizen Technologies in the Berlin Metropolitan Area and as a Chief Technology Officer of VINDEX GmbH in Berlin.

Dr Nicholas served as the Former Chief Executive Officer (CEO) of Metabolomic Discoveries GmbH, Berlin Area, Germany, a Metabolon, Inc. company that provides industry-leading global Precision Metabolomics (TM). He focused on a variety of areas, including Big Data Analytics in Medicine, Translational Research, Nutrition Research, Stable Isotope Labelling, Large Cohort Studies, Biomarker Research, Disease and Companion Diagnostics etc.

Dr Nicholas was the Former Managing Director of Germany Operations at Metabolon, Inc. in the Berlin Area, Germany. He then joined Biocrates Life Sciences AG, Innsbruck, Austria as a Co-Chief Executive Officer.

Dr Nicolas is passionate about starting and growing businesses and is dedicated to improving people's health and well-being both personally and communally.
By Qualification Dr Nicolas holds PhD in Biochemistry from the University of Potsdam, Germany, 2006.

Dr. Martin Forster is a health care professional brings over 17+ years of experience in drug development, clinical research focused on oncology. Dr Martin is an Associate Professor at UCL and Consultant Medical Oncologist at University College Hospital, London.

Martin graduated from the University of Newcastle upon Tyne and gained general medical experience in New Zealand, Australia, and the United Kingdom, becoming a member of the Royal College of Physicians (UK) in 2000. Since then, he has been working in cancer care, training in Medical Oncology at the Oxford Radcliffe and Royal Marsden NHS Trusts. During PhD, he was awarded the EORTC-PAMM Young Investigator Award.

More than 50 early- and late-phase clinical trials, ranging from first-in-human through registration Phase III trials, were conducted under Dr Martin’s direction. These include novel immunotherapies, solid cancer cell therapy research, and targeted treatments in precision oncology trials.

Dr Martin works closely with many national and international translational research teams, co-leads the Cancer Research UK Lung Cancer Centre of Excellence's clinical trials topic, and is headed as Chairperson of the National Institute of Health Research (NIHR) Head and Neck Research Group. He co-leads the London Cancer Chemotherapy Expert Reference Group and is the clinical lead for chemotherapy services at UCLH.

His areas of expertise are thoracic and head and neck cancers. He is particularly interested in drug development and in harnessing our growing knowledge of cancer biology to create study designs that identify patient populations most likely to benefit from novel medications and new medication combinations.

By Qualification Dr Martin completed MBBS from the University of Newcastle Medical School, UK,
PhD in Biochemistry from the Institute for Cancer Research/Royal Marsden Hospital, UK

Dr. Mark McHale is a health care professional with 45+ years of experience in renowned Pharma & Biotech industrial settings.

After completing his post-doctoral research fellowship in Molecular Biology at the University of East Anglia, England, he began working for SmithKline Beecham, now GlaxoSmithKline Plc, UK as a Senior Scientist Biotechnology & Neuroscience where he supported lead optimization projects in serotonin and dopamine receptors.

Dr McHale was a Chief Operating Officer at Theramyc, a biotech based in the United Kingdom and Australia, Currently Dr McHale is heading as a Chief Scientific Officer at Oak Hill, UK.

Dr McHale was the Co-Founder, Head of R&D, and Chief Development Officer at ASLAN Pharmaceuticals (NASDAQ:ASLN) in Singapore, where he was in charge of in-licensing various medications that target oncology and allergic inflammation.

Dr McHale had spent many years at AstraZeneca as Head of Molecular Sciences, Respiratory & Inflammation, where he oversaw the identification of all new targets for the treatment of asthma.

From CSL Behring, he obtained a license for ASLAN004, a first-of-its-kind therapeutic monoclonal antibody that targets IL-13Ra1. He then advanced this medication to a successful proof of concept in severe atopic dermatitis.

By qualification Dr McHale holds PhD in Molecular Biology from the University of East Anglia, England, 1989

Dr. Alan Richardson is a health care professional with 30+ years of experience in research, drug discovery and target identification in both academic and industrial settings.

After the post-doctoral training, Dr Alan started his career at Janssen Pharmaceutical in Belgium where he championed early efforts to discover kinase inhibitors, thereafter he worked at OSI Pharmaceutics on Kinase drug discovery on Cancer in UK.

Dr Alan subsequently joined the Institute of Cancer Research (ICR), London where he began one of his current research interests to discover drugs to combat drug resistance in cancer.

Currently he is performing research on drug resistance and focusing on the metabolism of branched-chain amino acids as well as heading the Department of Pharmacology in the School of Pharmacy and Bioengineering at Keele University, England.

Some of his research achievements include correctly analyzing subtypes of opioid receptors, the first demonstration of a biological role for focal adhesion kinase, and the discovery of some of the first Akt inhibitors.

Dr Alan has also explained why statins have not yet been effective anti-cancer agents, demonstrated the potential for BH3 mimics to work in synergy with carboplatin in the treatment of ovarian cancer, and most recently demonstrated how interfering with branched chain amino acid metabolism can make cells more sensitive to the chemotherapy drug paclitaxel.

By qualification Dr Alan Richardson holds PhD in Pharmacology from Cambridge University, England, 1990.

Dr Yann JAMIN is a healthcare professional with 15+ years of experience in developing practical imaging solutions to enhance decision making during the drug discovery process and accelerate the delivery of life-changing treatments to patients at the Institute of Cancer Research, London.

Yann led a successful translational programme of research integrating non-invasive imaging, digital pathology, artificial intelligence, and multi-omics data to expedite the delivery of precision oncology to children with cancer as a group leader by combining his cross-disciplinary technical knowledge and a strong network of expert collaborators.

Dr Yann has currently worked for Scintica Instrumentation as an applications scientist to guide scientists choose the best non-invasive imaging tools and devices to enhance and accelerate their preclinical research. He is extremely passionate about clinical research's ethical considerations.

As a Scientific Advisory Board Member Dr Yan is working for Children with Cancer UK, by providing scientific programmes & charity research with strategic direction and leadership.

He had published more than 50 peer-reviewed publications and has a track-record of contributing to global efforts to develop better and safer therapies and treatments.

By qualification Dr Yann holds PhD in Bio-Physics from The Institute of Cancer Research, London, 2009.